연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2024년 | 2023년 | 2022년 | 2021년 | 2020년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 179편 | 173편 | 163편 | 184편 | 135편 |
| 공동 | 147편 | 120편 | 115편 | 136편 | 168편 | |
| 합계 | 326편 | 293편 | 278편 | 320편 | 303편 | |
2167. Comparison of Iodine Density Measurement Among Dual-Energy Computed Tomography Scanners From 3 Vendors
Kim H, Goo JM, Kang CK, Chae KJ, Park CM
Invest Radiol. 2018 Jun;53(6):321-327
Link
2166. Monitoring tumor response to the vascular disrupting agent CKD-516 in a rabbit VX2 intramuscular tumor model using PET/MRI: Simultaneous evaluation of vascular and metabolic parameters
Ahn SY, Goo JM, Lee KH, Ha S, Paeng JC.
PLoS One. 2018 Feb 13;13(2):e0192706
Link
2165. Improving the prediction of lung adenocarcinoma invasive component on CT: Value of a vessel removal algorithm during software segmentation of subsolid nodules.
Garzelli L, Goo JM, Ahn SY, Chae KJ, Park CM, Jung J, Hong H.
Eur J Radiol. 2018 Mar;100:58-65
Link
2164. The Potential Role of Grid-Like Software in Bedside Chest Radiography in Improving Image Quality and Dose Reduction: An Observer Preference Study
Ahn SY, Chae KJ, Goo JM
Korean J Radiol. 2018 May-Jun;19(3):526-533
Link
2163. Evaluation of T categories for pure ground-glass nodules with semi-automatic volumetry: is mass a better predictor of invasive part size than other volumetric parameters?
Kim H, Goo JM, Park CM
Eur Radiol. 2018 Oct;28(10):4288-4295
Link
2162. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.
Kim M1, Kim TM2, Keam B1, Kim YJ3, Paeng JC4, Moon KC5, Kim DW1, Heo DS1.
Oncologist. 2019 Jan;24(1):20-e29. doi: 10.1634/theoncologist.2018-0464. Epub 2018 Sep 25.
Link
2161. Measurement of multiple solid portions in part-solid nodules for T categorization: Evaluation of prognostic implication
Kim H, Goo JM, Suh YJ, Hwang EJ, Park CM, Kim YT
J Thorac Oncol. 2018 Dec;13(12):1864-1872
Link
2160. Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
Yoo SH1, Keam B1,2, Kim M1, Kim TM1,2, Kim DW1,2, Heo DS1,2.
Thorac Cancer. 2018 Jun;9(6):736-744. doi: 10.1111/1759-7714.12641. Epub 2018 Apr 22.
Link
2159. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
Ock CY1, Yoo SH1, Keam B1,2, Kim M1, Kim TM1,2, Jeon YK3, Kim DW1,2, Chung DH3, Heo DS1,2.
Korean J Intern Med. 2018 Jun 29. doi: 10.3904/kjim.2018.011. [Epub ahead of print]
Link
2158. Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review.
Cheun H1, Kim M2, Lee H2, Oh KH2, Keam B3,4.
Invest New Drugs. 2018 Oct 8. doi: 10.1007/s10637-018-0673-y. [Epub ahead of print]
Link